Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pacira Pharmaceuticals has partnered with Quintiles Commercial US (Quintiles) and Integrated Commercialization Services (ICS) for the anticipated launch of its experimental postsurgical pain management drug Exparel (bupivacaine liposome extended-release injectable suspension).
Subscribe to our email newsletter
The results of the Phase 3 trial showed that the drug was well-tolerated and showed reduction in postsurgical pain over an extended period of time compared with placebo.
As per the terms of the deal Quintiles is responsible to provide a US sales force of around 70 people to support the sale of Exparel through December 2012 or beyond.
ICS will serve as the exclusive third party logistics provider to Pacira to support the US commercialization of Exparel for the next three years.
Pacira President and CEO David Stack said the company has made significant progress executing a launch strategy for Exparel that leverages the positive clinical data and supportive health outcome studies in anticipation of potential FDA approval in late October this year.